By reducing oxidative damage and supporting cellular homeostasis, the p62-NRF2 pathway may play a protective role in NAFLD progression, showing its potential as a therapeutic target [56]. The gene discussed is SQSTM1; the disease is metabolic dysfunction-associated steatotic liver disease.